Table 1 Demographic and clinical characteristics of the study population
From: Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
All | Diabetic | Hyperglycaemic | Normoglycaemic | P value | |
|---|---|---|---|---|---|
n | 551 | 151 | 253 | 147 | |
M/F, n (%) | 344/207 (62/38) | 103/48 (67/33) | 159/94 (65/35) | 82/65 (51/49) | 0.28† |
0.03§ | |||||
0.17# | |||||
Age (years) | 61 ± 0.7 | 67 ± 1.1 | 61 ± 0.9 | 55 ± 1.5 | <0.001† |
<0.001§ | |||||
<0.001# | |||||
BMI (kg/m2) | 27 ± 0.5 | 29 ± 1.4 | 27 ± 0.7 | 27 ± 1.1 | 0.009† |
0.009§ | |||||
0.009# | |||||
Hypertension, n | 164 | 66 | 68 | 30 | <0.001† |
<0.001§ | |||||
0.18# | |||||
ACE/ARB, n | 119 | 47 | 47 | 25 | 0.002† |
0.001§ | |||||
0.67# | |||||
Time to clinical improvement, d | 14.9 ± 0.5 | 20.2 ± 1.3 | 13.6 ± 0.6 | 12.8 ± 0.8 | 0.001† |
0.001§ | |||||
0.88# | |||||
Death, n (%) | 85 (15) | 42 (28) | 29 (11) | 14 (9) | 0.001† |
0.001§ | |||||
0.86# | |||||
Time to death, d | 11.4 ± 1.4 | 10.5 ± 2.1 | 11.7 ± 1.8 | 12.0 ± 1.9 | 0.009† |
0.009§ | |||||
0.009# | |||||
IL-6 (pg ml−1) | 79.1 ± 7.4 | 108.2 ± 18.7 | 74.6 ± 8.0 | 45.5 ± 9.5 | 0.14† |
0.007§ | |||||
0.38# |
